In Human Viral Challenge studies, healthy volunteers are isolated in our specialist facility and are infected with a suitable respiratory virus, which is manufactured according to the highest pharmaceutical standards. They are then observed for 10 to 17 days. During this time, they may be treated with a new drug candidate, or may have already been given a new vaccine. In addition, the company often works on virus-only research programmes with the intention of simply understanding how a virus and the human body interact - such research could lead to exciting new discoveries.
Conducting the Human Viral Challenge Model in a controlled quarantine environment allows for a superior study design; this is more cost-effective and critically accelerates the selection of a safe and effective dose, and dosing regimen, for a new antiviral drug or vaccine. We currently conduct and co-ordinate multiple clinical trials per year. To date, we have performed over 50 individual quarantines over more than 25 clinical studies, in which we have inoculated over 1075 volunteers. In this century, our experience in this field is unparalleled.
We believe that the Human Viral Challenge Model is a superior alternative to early stage, field-based trials, and could provide important guidance in designing the large-scale licensing studies that are required to move forward
To find out more about the services Retroscreen Virology provides, contact us on 020 7756 1300 and ask for Dr. Ian Meikle, Business Development Director.